Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.

Toon andere (1) versies

BACKGROUND: Tumour necrosis factor (TNF)-alpha inhibitors are beneficial for the treatment of rheumatoid arthritis (RA) in terms of reducing the risk of joint damage, improving physical function and improving quality of life. This Cochrane review is an update of a review of the treatment of RA with...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Ruiz Garcia, V, Jobanputra, P, Burls, A, Cabello, J, Vela Casasempere, P, Bort-Marti, S, Kynaston-Pearson, F
Formaat:	Journal article
Taal:	English
Gepubliceerd in:	2014

Gelijkaardige items

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
door: Ruiz Garcia, V, et al.
Gepubliceerd in: (2011)

Certolizumab pegol in therapy for rheumatoid arthritis
door: Galina Viktorovna Lukina, et al.
Gepubliceerd in: (2012-06-01)

Certolizumab pegol (CIMZIA®) for the treatment of rheumatoid arthritis
door: M Connock, et al.
Gepubliceerd in: (2010-10-01)

QUALITY OF LIFE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL
door: Vera Nikolayevna Amirdjanova, et al.
Gepubliceerd in: (2012-10-01)

New aspects of the pharmacotherapy of rheumatoid arthritis: a focus on certolizumab pegol
door: Evgeniy L'vovich Nasonov, et al.
Gepubliceerd in: (2011-02-01)

Multifocal tuberculosis on certolizumab pegol in a patient followed for rheumatoid arthritis
door: Emna Hannech, et al.
Gepubliceerd in: (2021-06-01)

New treatment possibilities for rheumatoid arthritis: the Russian experience in using certolizumab pegol
door: Dmitry Evgenyevich Karateev, et al.
Gepubliceerd in: (2012-04-01)

EFFICACY OF CERTOLIZUMAB PEGOL IN THE TREATMENT OF PSORIATIC ARTHRITIS
door: T. V. Korotaeva, et al.
Gepubliceerd in: (2015-10-01)

Certolizumab pegol – new option in the treatment of psoriatic arthritis
door: Maria Majdan, et al.
Gepubliceerd in: (2014-07-01)

Certolizumab pegol in the treatment of spondyloarthritis
door: Mariusz Korkosz
Gepubliceerd in: (2014-09-01)

Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritis
door: Smolen, JS, et al.
Gepubliceerd in: (2024)

COST-EFFECTIVENESS OF CERTOLIZUMAB PEGOL PLUS METHOTREXATE OR AS MONOTHERAPY FOR THE TREATMENT OF ACTIVE RHEUMATOID ARTHRITIS IN THE UNITED KINGDOM
door: Purcaru, O, et al.
Gepubliceerd in: (2010)

Prefilled certolizumab pegol (Cimzia&reg;) syringes for self-use in the treatment of rheumatoid arthritis
door: J Rosa, et al.
Gepubliceerd in: (2010-08-01)

CERTOLIZUMAB PEGOL IN THE TREATMENT OF AXIAL SPONDYLOARTHRITIS
door: Sh. F. Erdes
Gepubliceerd in: (2016-02-01)

Eosinophilic Annular Erythema Due to Certolizumab Pegol Therapy for Rheumatoid Arthritis Post-COVID-19 Vaccine
door: Andrea Bassi, et al.
Gepubliceerd in: (2023-04-01)

The efficacy of certolizumab pegol in rheumatoid arthritis assessed by gray scale and power Doppler ultrasonography: case reports
door: José Alexandre Mendonça, et al.
Gepubliceerd in: (2019-02-01)

Exposure–Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis
door: Stéphane Paul, et al.
Gepubliceerd in: (2020-07-01)

Drug Induced Thrombotic Microangiopathy with Certolizumab Pegol
door: Mehmet Baysal, et al.
Gepubliceerd in: (2018-09-01)

Treatment of pyoderma gangrenosum in pregnancy with certolizumab pegol
door: Lindsey J. Wanberg, et al.
Gepubliceerd in: (2024-06-01)

Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: Post-hoc analysis of clinical trials
door: Tanaka, Y, et al.
Gepubliceerd in: (2023)

Experience with long-term use of certolizumab pegol (Cimzia)
door: Karine Arnoldovna Lytkina, et al.
Gepubliceerd in: (2013-10-01)

Experience with long-term use of certolizumab pegol (Cimzia)
door: Karine Arnoldovna Lytkina, et al.
Gepubliceerd in: (2013-10-01)

A genome-wide screen for variants influencing certolizumab pegol response in a moderate to severe rheumatoid arthritis population.
door: Ian R White, et al.
Gepubliceerd in: (2022-01-01)

A genome-wide screen for variants influencing certolizumab pegol response in a moderate to severe rheumatoid arthritis population
door: Ian R. White, et al.
Gepubliceerd in: (2022-01-01)

Long-Term Durability of Certolizumab Pegol in Patients with Rheumatoid Arthritis Over 5 Years: An Analysis of Pooled Clinical Trial Data
door: Vivian P. Bykerk, et al.
Gepubliceerd in: (2023-02-01)

Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study
door: Glatt, S, et al.
Gepubliceerd in: (2019)

Quantitation of certolizumab pegol by validated liquid chromatography methods
door: Clóvis Dervil Appratto Cardoso Júnior, et al.
Gepubliceerd in: (2023-11-01)

Certolizumab pegol in treatment of Crohn's disease with perianal lesions
door: I.L. Khalif, et al.
Gepubliceerd in: (2018-04-01)

Active axial spondyloarthritis: potential role of certolizumab pegol
door: Ranatunga S, et al.
Gepubliceerd in: (2014-02-01)

Certolizumab pegol w leczeniu reumatoidalnego zapalenia stawów
door: Piotr Wiland, et al.
Gepubliceerd in: (2011-08-01)

An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy
door: Acosta-Felquer ML, et al.
Gepubliceerd in: (2016-03-01)

CERTOLIZUMAB PEGOL IN THE TREATMENT OF TAKAYASU ARTERITIS: THE FIRST EXPERIENCE AND PROSPECTS
door: P. I. Novikov, et al.
Gepubliceerd in: (2018-07-01)

Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol.
door: Hazes, J, et al.
Gepubliceerd in: (2010)

Rapid effectiveness of certolizumab pegol in non-radiographic axial spondyloarthritis
door: A. Spadaro, et al.
Gepubliceerd in: (2013-07-01)

Patient Adherence and Efficacy of Certolizumab Pegol in the Management of Crohn's Disease
door: Wojciech Blonski, et al.
Gepubliceerd in: (2012-04-01)

Efficacy and tolerability of certolizumab pegol in Crohn's disease in clinical practice
door: O V Knyazev, et al.
Gepubliceerd in: (2018-06-01)

Certolizumab pegol – Tumor necrosis factor inhibitor for refractory uveitis
door: Yael Sharon, et al.
Gepubliceerd in: (2020-06-01)

Possible relationship between certolizumab pegol and arrhythmias: report of two cases
door: R. Talotta, et al.
Gepubliceerd in: (2016-09-01)

Effectiveness of Certolizumab Pegol in Treating Rheumatoid Arthritis Patients with Persistent Inflamed Residual Mono- or Oligosynovitis Resistant to Prior TNF-α Inhibitors
door: Syuichi Koarada, et al.
Gepubliceerd in: (2015-01-01)

Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment
door: Jeffrey R. Curtis, et al.
Gepubliceerd in: (2017-12-01)